

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

ANNOUNCEMENT IN RESPECT OF MEDIA REPORTS

The board of the directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company”) noted the recent Hong Kong media reports regarding that Hong Kong Department of Health has received a complaint in relation of an export medicine of the Company’s Hong Kong production plant and to investigate in the Company’s Hong Kong production plant.

The Company confirms that the Department of Health has recently visited the Company’s Hong Kong production plant to investigate the allegation in the complaint. The Company is informed that the Department of Health is still investigating the incident and the Hong Kong production plant is not required to suspend its production. Our Hong Kong production plant has fully co-operated with the investigation. Meanwhile, the Company is also conducting an internal review in respect of this incident.

The United Laboratories Group has always attached great importance to pharmaceutical production management and strict quality control. The Hong Kong production plant has obtained the GMP certification. Our exported medicine from the Hong Kong production plant has been performed microbial testing by independent third-party accredited laboratory. Microbial tests are done before any product is shipped as part of our stringent quality control measures. The Group’s turnover in 2014 amounted to HK\$8.03 billion and Hong Kong production plant shared less than 4% of the Group’s turnover. The Board considers that the incident would not have material adverse impact on the Group’s operations and financial position.

By Order of the Board
**The United Laboratories
International Holdings Limited**
Tsoi Hoi Shan
Chairman

Hong Kong, 17 August 2015

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Mr. Huang Bao Guang, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.